Journal of Hematology and Oncology Research

Journal of Hematology and Oncology Research

Journal of Hematology and Oncology Research – Instructions For Author

Open Access & Peer-Reviewed

Submit Manuscript

Instructions for Authors

A detailed technical and ethical guide for researchers contributing to the Journal of Hematology and Oncology Research.

Advancing Global Clinical Evidence

Journal of Hematology and Oncology Research (JHOR) 2372-6601 is an international, peer-reviewed, open-access journal dedicated to the swift publication of high-impact research across the full spectrum of hematology and oncology.

We welcome submissions from clinicians, researchers, and pharmaceutical professionals that define the next generation of cancer therapies and diagnostic innovations.

1. Submission Channels & Process

Authors should choose the submission channel that best aligns with their technical requirements and institutional policies. JHOR provides seamless integration across multi-device platforms.

Manuscript Zone

Our flagship editorial management system. It provides a robust interface for multi-file uploads, real-time tracking of peer-review milestones, and direct communication with Guest Editors.

Login to Manuscript Zone →

Simplified Submission

A streamlined, mobile-optimized form designed for efficient submissions without the need for initial account registration. Ideal for rapid communications and case images.

Access Simple Form →

Direct Email

Direct attachment submission to our central editorial office. Once received, your manuscript will be assigned a unique acknowledgment ID within 72 hours.

[email protected]
First-Time Authors: When utilizing Manuscript Zone, ensure you verify your institutional email address. Complete your professional profile with your discipline and primary research interests to facilitate accurate reviewer matching. Retain your login credentials for long-term tracking.
2. Manuscript Structure & Narrative Flow

Scientific clarity is established through logical organization. Manuscripts must be stand-alone works that present clinical evidence without dependency on external supplemental data for core conclusions.

Front Matter Components
  • Article Title: Must be descriptive, concise (max 30 words), and relevant. Avoid non-standard abbreviations that may hinder electronic indexing.
  • Complete Author Metadata: Full names, physical addresses, phone numbers, and discipline. Explicitly identify the Corresponding Author, whose address will remain the primary contact point throughout the pre- and post-publication lifecycle.
  • Running Title: A short header (max 60 characters) to be displayed atop printed pages.
  • Keywords: 5 to 12 strategically chosen terms. Effective keywords improve discoverability in major clinical databases (PubMed, Scopus, etc.).
  • Abstract: Maximum 250 words. A single, non-subheaded paragraph providing a concise summary of research objectives, methodologies, statistical results, and clinical significance.
The IMRAD Core

Introduction (Max 500 words)

Briefly state the research objectives and provide sufficient background to clarify why the study was undertaken. It should clearly define the clinical gap being addressed and the specific hypotheses tested.

Materials & Methods (Technical Depth)

Provide brief but sufficiently complete information to permit a qualified reader to replicate the experiments. Cite established procedures via references; only truly innovative modifications should be detailed. Clearly state the gender of subjects and list all companies/suppliers for materials used.

Results

Present experimental findings precisely. Include only results essential to establishing the core point of the work. All numerical data must be analyzed using appropriate, robust statistical tests.

Discussion & Speculation

Maximum 1500 words. interpret findings in light of related published work. Spectulations are permitted but must be clearly identified as such and grounded in the presented evidence.

End Matter & Transparency
  • Conclusion: Summarize principal findings within a realistic clinical framework. Assess potential applications in political, social, or technical arenas where relevant.
  • Acknowledgments: Identify all funding sources (grants, institutional support). Acknowledge technical assistance from individuals who do not meet authorship criteria, ensuring they have consented to the recognition.
  • Conflict of Interest (COI): Authors must disclose any associations—consultancies, financial interests, or intellectual property rights—that represent a potential conflict. A footnote may be added to the final publication if necessary.
  • Supplemental Data: While manuscripts must be stand-alone, additional data (videos, large tables) may be submitted. These undergo the same rigorous peer review and will be published online only if they substantially contribute to the work.
3. Scientific Formatting Standards
Technical Node Standard Specification
References Numbered consecutively by appearance. List first five authors, then "et al." Accuracy is the author's responsibility. Include DOI links for all clinical citations.
Footnotes Used for unpublished observations or personal communications. Authors must provide written approval from any individual cited in a footnote.
Tables & Legends Submit each table on a separate page at the end of the manuscript. Titles and legends must provide sufficient detail for the table to stand alone.
Figures & Art High-resolution files required. Symbols and text must be no smaller than 2mm after reduction. Legends must be placed immediately below the figure.
Abbreviations Must be defined in a single consolidated footnote immediately after the first abbreviation is cited in the main text.
4. Research Ethics & Compliance

JHOR enforces the highest standards of integrity. We align with the Committee on Publication Ethics (COPE) and the ICMJE to maintain zero tolerance for malpractice.

Human Subjects

Obtain informed consent only after full disclosure of potential outcomes. Maintain strict confidentiality. Never influence participants through disproportionate rewards for participation.

Animal Research

Experiments must comply with international Care and Use rules. Precautionary ethical measures and institutional approvals must be explicitly documented in the Methods section.

Scientific Truth

Plagiarism, scientific fraud, and duplicate submissions are considered serious misconduct. JHOR reserves the right to notify institutional boards if such breaches are identified.

Copyright & Licensing: JHOR is licensed under Creative Commons Attribution 4.0 (CC BY 4.0). This allows authors to retain their rights while enabling the clinical community to copy and distribute work freely, provided appropriate citation credit is given.
5. Editorial Scope & Accepted Types

JHOR accepts a wide variety of manuscript styles to accommodate different research depths:

  • Primary Research: Original Research Papers, Clinical Trials, Methodological Innovations.
  • Reviews: Comprehensive Reviews, Literature Reviews, Mini-Reviews, Book Reviews.
  • Rapid Feedback: Rapid Communications, Letters to the Editor, Editorials, Commentaries.
  • Case Evidence: Case Reports, High-Resolution Case Images.
  • Academic: Thesis Overviews, Conference Proceedings, Perspectives, Opinions.

Publish Your Clinical Breakthrough

Your research has the power to change clinical practice. Follow these guidelines to ensure a smooth, professional submission process.

Transparency & Support: We charge only appropriate publication fees for accepted manuscripts to maintain our subscription-free model. There are no submission fees. For assistance, contact [email protected].

Advancing clinical truth through excellence. Last updated: January 2026.